Gilead Sciences Inc (GILD) — 分析摘要
Gilead Sciences Inc（GILD）的市值为181.18十亿美元，最近一年的营收同比增长了+2.4%。净利润率为28.9%。当前市盈率为-55.9倍。
核心要点
- 营收同比变化+2.4%
- 净利润率28.9%
- 市盈率-55.9倍
与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比，GILD的营收增长为+2.4%，市盈率为-55.9倍。
Gilead Sciences Inc (GILD)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -2.5x — 盈利不足以覆盖利息支出
净利润由上一期盈利转为亏损。
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
行业
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
员工人数
17,000
总部
FOSTER CITY, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$3.28
股息收益率
2.24%
股息历史
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。